DRL's Raga Glitazar to hit market by 2004
The second compound, a duel action insulin sensitiser christened ' Raga Glitazar' which is presently under going phase-III clinical trials with Novo Nordisk is expected to enter the market by 2004,
The second compound, a duel action insulin sensitiser christened ' Raga Glitazar' which is presently under going phase-III clinical trials with Novo Nordisk is expected to enter the market by 2004,